ORHUB Inc. (ORHB)

[logytwo]

You can't leave it at that my friend!

[Nazar3]

Buckle in.

[logytwo]

I see they have submitted financials, while they weren't great, they should at least bring the stock current and remove the "Yield" label from the symbol.

[Elena R]

New bio active glass
https://www.beckersspine.com/spine/55747-hippofi-debuts-new-bioactive-glass-for-spine-fusion-procedures.html
HippoFi’s (PUR) new technology plus their last deal is game changer. This company has so much future

[logytwo]

HippoFi’s Regenerative Therapeutics Division, Launches PURbridge™ for Spine Surgery**

PURbridge 11.2022 final
PURbridge™, an advanced synthetic and new form of bioactive glass, is positioned to significantly increase the Company’s revenue throughout 2023

IRVINE, CA / November 23, 2022 / HippoFi, Inc. (formerly ORHub), (OTC Pink: ORHB), a diversified company focused on the biotech and fintech segments, is proud to announce its newest biologic product, PURbridge™. This new form of active bioglass expands the already extensive portfolio of HippoFi’s division of Regenerative Therapeutics, which continues to target a total Spine market, anticipated to reach $18 billion in 2023.

“Successful lumbar and thoracic spine fusion surgeries require biological products to bridge new bone growth between vertebral bodies. PURbridge™ is uniquely positioned to solve this critical patient need and desired surgical outcome. Our proprietary bridge-like structure has been specifically formulated by interweaving bioactive glass and our absorbent Tri-pore NanoCrystals™with flexible fibers of semi-crystalline molecules of collagen. This unique composition of three highly biocompatible elements results in a flexible and strong ‘bioactive bridge’ which holds its shape and position while helping the patient heal, spanning the intended area with solid bone,” explained Ryan Fernan, Head of PUR Biologics.

“Our purpose as an emerging healthcare leader is to provide innovative biotech products and fintech software to generate extraordinary growth in revenue, market presence, and innovation,” stated CJ Wiggins, Founder, Executive Chairman & CEO of HippoFi. “PURbridge™ is an outstanding clinical solution which immediately expands our product portfolio of advanced synthetics in Spine. We are committed to become the global leader in biological products for growing bone in spine procedures, to lead the future of regenerative therapeutics in regenerating joint cartilage and spinal disc, and to become the first financier and digital payment platform for all surgically implanted products between hospitals, ASC, and medical device vendors.”

HippoFi is traded on the OTC under the symbol “ORHB”.

[logytwo]

HippoFi accesses Precision Spine's major sales channels to speed its sales strategy & quickly drive revenue

IRVINE, CA / ACCESSWIRE / October 5, 2022 / HippoFi, Inc. - formerly ORHub® (OTC PINK:ORHB) announced today it has signed a strategic agreement with Precision Spine, Inc.® (www.PrecisionSpineInc.com). "This agreement will help to accelerate growth and drive revenue by selling the entire PUR Biologics product line and future HippoFi innovations. With Precision's strong presence in the Spine market, we expect a substantial increase in our revenues and brand recognition," stated CJ Wiggins - Executive Chairman & CEO of HippoFi (www.HippoFi.com).

HippoFi's regenerative therapeutics division, PUR Biologics® (www.PURbiologics.com), is focused on advanced biological solutions for spine surgery and provides Precision Spine the ability to immediately sell a full line of biologic products alongside their broad spine implant portfolio. "This deal allows HippoFi to drive new sales through Precision's vast and growing network, which already includes revenue producing accounts with more than 280 hospitals and approximately 340 spine surgeons. I expect this partnership will bring the speed and product commercialization we are looking for with Precision's 180+ sales distributors," shared Ryan Fernan - Head of PUR Biologics. "I am excited to work with Precision Spine's seasoned commercial team to bring our premium products and future technologies to patients and surgeons."

Precision Spine's Chief Operating Officer, Christopher DeNicola, expressed, "This strategic partnership is a significant achievement, representing an opportunity to strengthen and expand the presence of both companies in the growing global spine market." "I believe that with North America driving growth, that the entire orthopedic market will reach $75B over the next eight years; biologics contributing about 20% ($15B) and Spine alone, exceeding $16B (75% medical device + 25% biologics)," concluded CJ Wiggins.

[logytwo]

Elena, do you know anything about SRM that was to launch in 2nd qtr or FutureORTM that is to launch in qtr 3 (need to hurry)?

[Elena R]

The company is making revenue!!!!
The company already has biotech products that are being sold into the market with the acquisition of PUR Biologics

[logytwo]

Shareholders Letter

From the desk of
CJ WIGGINS
FOUNDER, EXECUTIVE CHAIRMAN & CEO
of
HIPPOFI, INC.
Ticker: “ORHB”

Dear Shareholders,
I am writing to you, to share our team’s accomplishments over the last 5 months and inform all parties we have changed our name to best reflect the company’s current position & financially focused business model. HippoFi® is a fast-moving finance & healthcare innovator, implementing first-to-market solutions to leverage our team’s successful sales background, industry specific expertise, & proven public company track-record, into three of today’s hottest multibillion-dollar markets: FINTECH, BIOTECH, & ARTIFICIAL INTELLIGENCE.
Focused on driving value to our customers and shareholders, we have completed significant milestones to bring the company’s initial products and services to commercialization and anticipate significant revenues. In this short period, we established the current business model, activated our acquisition strategy, procured new products & technologies, streamlined operational management, expanded sales channels, and executed agreements with strategic affiliates.
While remaining capitalized and meeting the new SEC reporting requirements, Marcum & HTFL continue as our accounting & SEC representatives. With the sale of Surgical Spotlight and elimination of company debt, the courts dismissed “with prejudice” all litigation which once was holding the company back. Immediately following this relief, we quickly focused on entering the fintech market and completed developing our new surgical software platform to enable faster financial transactions between hospitals and medical device vendors. I am also pleased to bring to your attention, we have entered into partnership discussions and exclusive agreements with globally recognized players in this target market.
To fully engage our expertise & existing sales channels, the acquisition of PUR Biologics® has proven to add significant value with proprietary cell-derived technologies focused on bone & cartilage regeneration. Along with the existing line of commercialized products, PUR quickly launched PUR Pillars™ as a part of the new product portfolio. Independently managed by its experienced biotech leadership & scientific team, we are actively negotiating the rights to a breakthrough technology which addresses current product limitations & patient safety in growing bone & specifically relating to PUR’s focus on “spine fusion” surgeries. PUR’s products are the first to flow through our new surgical software and “fast-pay” vendor payment system.
We continue to open additional opportunities to commercialize our surgical products and financial software as we wrap up late-stage discussions with an anticipated sales partner. This partnership will allow our digital and biological solutions to be supported by approximately “150+ representatives”, targeting “200+ hospitals”. In preparation of our growth and success, we hired our head of sales last month for the US markets and are now equipped with a dedicated sales leader having the proven skills and relationships needed to increase adoption and revenue.
As sales experts in medical technologies & innovators in “first-of-kind” healthcare solutions, the proven power of Artificial Intelligence is a natural fit for our company. I am very excited to share with you, we have executed an “Exclusive Letter of Intent” with a global AI expert. This amazing deal solidifies the third division in our business design with a fully managed and operational product and technical partner. In the next 30 days, we plan to secure this multi-billion-dollar market opportunity by closing our definitive agreement and together, plan to introduce our validated & commercial-ready AI platform to the US market - helping save lives with the latest in AI technologies to improve the detection and prediction of various forms of Cancer.
Stay tuned as our execution continues, momentum builds, and revenues grow. We value your support of HippoFi® as we help do our part in shaping the future of healthcare.
Sincerely,
CJ

[Elena R]

HIPPOFI leverages three hottest multibillion dollar markets
This company has produced a fast pay system for healthcare, that is a big deal!!! The market is over three hundred billion dollars and this company has one of a kind solution.

[logytwo]

New Website:https://hippofi.info/

[logytwo]

Is that you Rick? Is it true the best revenge is success.

[Derpo]

What a bunch of grifters. Give them your money people, I'm sure it will work out this time!

[logytwo]

Born from ORHub®, HippoFiTM represents the company's fintech focus with commitment to the ‘Hippocratic oath' and patient clinical improvements.

IRVINE, CA / ACCESSWIRE / August 24, 2022 / ORHub, Inc. (OTC PINK:ORHB) announces today its future as "HippoFi" (HippoFi.com) a fintech and healthcare innovator, implementing first-to-market solutions to leverage three of the hottest multibillion-dollar markets: FINTECH, BIOTECH, & ARTIFICIAL INTELLIGENCE.

"HippoFi ("formally ‘ORHub"") is crafting the future by delivering revolutionary technologies and innovative solutions specifically targeted at an annual US market spend approaching $300 billion. The timing could not be better to update the company's name and brand as we are actively engaging in new partnerships, continued acquisition efforts, and deploying novel digital & biological solutions. We deliver financial value and savings to customers and clinical improvements to patients, while benefiting from scalable, high-growth, & high-profit opportunities. The name ‘HippoFi' & new company brand best represents our shaping healthcare's bright future with never-seen-before fintech, biotech, and AI technologies, along with our commitment to push boundaries and driving value to customers, shareholders, and most importantly for the patients," shared CJ Wiggins, Founder, Executive Chairman & CEO "As hospitals & med-device vendors continue the necessary efforts of becoming more efficient, effective, and advancing the quality of patient care, HippoFi will soon be recognized as being "The Only Way to OperateTM".

HippoFi's (formally ORHub's) web site will continually be updated, and a new Ticker Symbol will soon represent HippoFi (formally ORHub), while continuing to trade on the OTC: ORHB while moving the company status forward to OTC-QB, targeting a future NASDAQ listing.

[logytwo]

ORHUB, Inc.
Thu, July 28, 2022 at 3:00 AM
In this article:

ORHB
0.00%

PUR PillarsTM were designed specifically for spine surgery, with a patient's post-surgical outcomes in mind.

IRVINE, CA / ACCESSWIRE / July 28, 2022 / ORHub, Inc. (OTC Pink:ORHB) plans to launch its new bone growth product focused on spine surgery in early Q4 2022.

Spinal fusion surgeries require implanting biological products or materials to help support and stimulate the patient's natural healing and fusion. Today's US spine market and ORHub's opportunity includes an estimated 950,000 surgical spine fusion procedures per year, with a conservative annual growth rate of six percent.

"PUR's PillarsTM design aims to achieve optimal patient outcomes by keeping bone graft materials in place, avoiding the typical migration of bone graft material from the desired location and eliminating inactive carriers," shared Ryan Fernan, Head of PUR Biologics. "PUR's PillarsTM are created from our Fibrous CollagenTM and deliver a solid matrix structure designed to act as a Bio-active BridgeTM for a patient's natural cells and growth factors to bind with."

Market estimates for "bone growth" products and related therapeutics are believed to be greater than $8B, increasing the opportunity for revenue, value, and scalability which ORHub has positioned with the PUR Biologics brand.

[logytwo]

ORHUB, Inc.
Wed, July 27, 2022 at 11:30 AM
In this article:

ORHB
0.00%

A proven industry leader and executive, Ryan Fernan, will help ORHub advance Ortho-Spine technology beyond current limitations.

IRVINE, CA / ACCESSWIRE / July 27, 2022 / ORHub, Inc. (OTC Pink:ORHB) officially kicks off the acquisition of PUR Biologics ("PUR") with the appointment of Ryan Fernan as the Head of PUR Biologics. An ORHub biotech company, PUR Biologics is focused on delivering next generation regenerative biologic products to address degenerative musculoskeletal diseases.

Mr. Fernan, brings direct access to a broad industry network with a proven track record of over 18 years in the medical device and biotechnology industry. Recognized as a frontrunner in sales and product development, Mr. Fernan's career included leadership roles associated with Johnson&Johnson/DePuy Spine, and then Zimmer/Biomet. With a strong entrepreneurial drive, Mr. Fernan also founded OC Surgical, Inc., which became the largest Actifuse distributor in the United States from UK-based orthobiologics company, ApaTech. His successes with Actifuse largely contributed to its purchase by Baxter (NYSE: BAX) for approx. $330M in 2010. Mr. Fernan went on to found PUR Biologics, quickly developing technologies from concept, through pre-clinical trials, to large animal trials in collaboration with the University of Colorado and UCSD, and into initial FDA human clinical trial discussions. These first- generation technologies were negotiated into a successful sale by Mr. Fernan to Histogen, Inc. (NASDAQ: HSTO), while he continued directing the licensing and development of the next generation of cell derived extracellular matrix technologies.

"Mr. Fernan has already hit the ground running, identifying multiple technologies which we are evaluating for acquisition or licensing," said CJ Wiggins - ORHub Founder, Executive Chairman & CEO. "Our intention with these potential deals is to place PUR in a leading position of today's bone growth market and tomorrow's advanced ortho-spine solutions. I am proud to have Ryan lead our Regenerative Therapeutic efforts and am excited by the plans to change how unmet patient needs will be addressed."

"I am focused on significantly improving clinical outcomes, while generating revenue, and have already secured many strategic sales opportunities. We are now completing our industry leading portfolio of advanced ortho-spine biologics," added Ryan Fernan, new Head of PUR Biologics. "We will be aligning with key opinion and industry leaders, who will support our highly innovative products and in turn, assist us in developing our new cell derived technologies addressing the osteoarthritis, cartilage regeneration, and the mitigation of pain."

With PUR's proprietary technologies, market access, and proven track record in product development, ORHub's Regenerative Therapeutic division is poised to impact multiple therapy markets that exceed a combined $40B in annual revenue.

[logytwo]

ORHUB, Inc.
Thu, July 21, 2022 at 6:00 AM
In this article:

ORHB
+7.00%

ORHub's new Surgical Resource Management ("SRM") platform, FutureOR, facilitates faster Case-to-Cash payments to medical device and biological vendors.

IRVINE, CA / ACCESSWIRE / July 21, 2022 / ORHub, Inc. (OTC PINK:ORHB) takes form as a medical fintech company, announcing the launch of "FutureOR", its SRM platform, focused on enabling digital connectivity, faster vendor payments, and surgical implant accountability.

The Company "intends to eliminate the deficiencies faced by hospitals and their vendors, replacing outdated documentation and legacy processes with ORHub's uniform business automation and fast-pay software," shared Founder, Executive Chairman & CEO, CJ Wiggins. "This software can reduce the Case-to-Cash timeline (hospital to vendor) by over 90% as well as bring real-world value to the FDA's Unique Device Identifier (UDI) mandate for implant accountability."

"As we ready this powerful software for release, initial focus is on the ortho-spine surgical markets with a 12-month target of 200 hospitals," continues Mr. Wiggins. "These facilities implant an estimated $2B+ in implanted ortho-spine devices and materials, providinga unique opportunity for our business model. Considering the scale of the deficiencies we aim to fix with our digital solution and financial instruments, along with the tightly concentrated customer base, I am confident in ORHub becoming a significant Fintech business.

[logytwo]

Nice to see the Bid / Ask tightening up.

[logytwo]

Nice to see the Bid / Ask tightening up.

[Thugmuffin]

$ORHB ORHub Retains Predica to Launch New Software PlatformPress Release | 06/09/2022

"ORHub to launch new FutureORTM application in Q3 2022"

IRVINE, CA / ACCESSWIRE / June 9, 2022 / ORHub, Inc. (OTC PINK:ORHB) announced today it will launch its new application FutureORTM next quarter and has expanded its relationship with Predica to support the release, provide managed services, and help transform the business of surgery. FutureORTM will bring to the medical device industry surgical implant accountability, improved business efficiency, and fast payments between hospitals and vendors. "As ORHub's technology partner, Predica is honored to have played a part in such a transformative solution as FutureORTM. From the onset, FutureORTM was clearly purpose-built to streamline processes for both Hospitals and their Bio-Medical Device vendors. This approach increases efficiency and digital payments between the stakeholders, but more importantly, will offer opportunities to reduce the overall cost of healthcare in the United States" shared Pete Orologas - Vice President and Managing Partner of Predica US.

A Microsoft Gold partner, Predica (predicagroup.com) is an international cloud-native provider of Azure cloud development and management services, serving blue-chip enterprise customers in Europe, the Middle East, and the United States. The company specializes in applications and DevOps, cloud infrastructure, security and data analytics in order to drive digital transformation with their customers and has been instrumental in the development of FutureORTM. "We are very pleased to continue our relationship with Predica," stated CJ Wiggins - Founder, Executive Chairman, President & CEO of ORHub. "We have worked closely with Predica's team and leadership to develop FutureORTM. Their continued involvement will ensure a successful launch of our new platform. The release of FutureORTM will empower ORHub to continue its growth as a finance-focused SaaS."

--------------

About ORHub, Inc.
ORHub, Inc. (OTC: ORHB) is headquartered in Irvine, California. The company is focused on the Internet of Things (IoT), creating Intelligent Automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHub's solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility. More Information please visit www.ORHub.com

ORHub, Inc.
6865 Alton Pkwy, Suite 210
Irvine, CA 92618

About Predica, Inc.

Predica is a global provider of Azure consulting and development services. We are a long-term Microsoft Partner, named Azure Expert Managed Serviced Provider, awarded with 8 Advanced Specializations and 15 Gold Competencies. From building scalable applications and implementing DevOps, through cloud migration, governance and optimization, to customized data solutions and managed security services, we use full-stack Microsoft technology to inspire a self-managed culture and enable personal success for all our clients.

With 380+ professionals on board and 9 office locations worldwide, Predica has delivered over 1800 successful projects to around 350 customers in 26 countries. In February, 2022 the company joined SoftwareOne, a leading global provider of end-to-end software and cloud technology. For more information, please visit https://www.predicagroup.com.

Predica Inc.

9655 Granite Ridge Drive, Suite 200
San Diego, California 92123
Riedenmatt 4, CH-6370 Stans

###

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ORHub's products and services, the results from use of ORHub's products and services, and general business conditions, particularly within the surgical, life science, and medical device industries. Any forward-looking statements contained in this press release are based upon ORHub's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ORHub's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Further information on potential risks that could affect actual results will be included in future filings made by ORHub and are available on the Company's website at ORHub.com from time to time.

Contact:

Jason Brown
ORHub, Inc.
612-209-7565

SOURCE: ORHUB, Inc.


View source version on accesswire.com:
https://www.accesswire.com/704472/ORHub-Retains-Predica-to-Launch-New-Software-Platform

[Thugmuffin]

$ORHB ORHUB RETAINS PREDICA TO LAUNCH NEW SOFTWARE PLATFORMPress Release | 06/09/2022


"ORHub to launch new FutureORTM application in Q3 2022"


ORHub, Inc. (OTC Pink: ORHB) announced today it will launch its new application FutureORTMnext quarter and has expanded its relationship with Predica to support the release, provide managed services, and help transform the business of surgery. FutureORTMwill bring to the medical device industry surgical implant accountability, improved business efficiency, and fast payments between hospitals and vendors. As ORHubs technology partner, Predica is honored to have played a part in such a transformative solution as FutureORTM. From the onset, FutureORTM was clearly purpose-built to streamline processes for both Hospitals and their Bio-Medical Device vendors. This approach increases efficiency and digital payments between the stakeholders, but more importantly, will offer opportunities to reduce the overall cost of healthcare in the United States shared Pete Orologas - Vice President and Managing Partner of Predica US.


A Microsoft Gold partner, Predica (predicagroup.com)isan international cloud-native provider of Azure cloud development and management services, serving blue-chip enterprise customers in Europe, the Middle East, and the United States. The company specializes in applications and DevOps, cloud infrastructure, security and data analytics in order to drive digital transformation with their customers and has been instrumental in the development of FutureORTM. We are very pleased to continue our relationship with Predica, stated CJ Wiggins - Founder, Executive Chairman, President & CEO of ORHub. We have worked closely with Predicas team and leadership to develop FutureORTM. Their continued involvement will ensure a successful launch of our new platform. The release of FutureORTMwill empower ORHub to continue its growth as a finance-focused SaaS.


--------------


About ORHub, Inc.
ORHub, Inc. (OTC: ORHB) is headquartered in Irvine, California. The company is focused on the Internet of Things (IoT), creating Intelligent Automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHubs solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility. More Information please visit www.ORHub.com


ORHub, Inc.

6865 Alton Pkwy, Suite 210

Irvine, CA 92618



About Predica, Inc.

Predica is a global provider of Azure consulting and development services. We are a long-term Microsoft Partner, named Azure Expert Managed Serviced Provider, awarded with 8 Advanced Specializations and 15 Gold Competencies. From building scalable applications and implementing DevOps, through cloud migration, governance and optimization, to customized data solutions and managed security services, we use full-stack Microsoft technology to inspire a self-managed culture and enable personal success for all our clients.


With 380+ professionals on board and 9 office locations worldwide, Predica has delivered over 1800 successful projects to around 350 customers in 26 countries. In February, 2022 the company joined SoftwareOne, a leading global provider of end-to-end software and cloud technology. For more information, please visit https://www.predicagroup.com.


Predica Inc.

9655 Granite Ridge Drive, Suite 200
San Diego, California 92123

Riedenmatt 4, CH-6370 Stans


###


Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ORHubs products and services, the results from use of ORHubs products and services, and general business conditions, particularly within the surgical, life science, and medical device industries. Any forward-looking statements contained in this press release are based upon ORHubs historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ORHubs expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Further information on potential risks that could affect actual results will be included in future filings made by ORHub and are available on the Companys website at ORHub.com from time to time.


Contact:

Jason Brown

ORHub, Inc.

612-209-7565

[logytwo]

"ORHub to launch new FutureORTM application in Q3 2022"

IRVINE, CA / ACCESSWIRE / June 9, 2022 / ORHub, Inc. (OTC PINK:ORHB) announced today it will launch its new application FutureORTM next quarter and has expanded its relationship with Predica to support the release, provide managed services, and help transform the business of surgery. FutureORTM will bring to the medical device industry surgical implant accountability, improved business efficiency, and fast payments between hospitals and vendors. "As ORHub's technology partner, Predica is honored to have played a part in such a transformative solution as FutureORTM. From the onset, FutureORTM was clearly purpose-built to streamline processes for both Hospitals and their Bio-Medical Device vendors. This approach increases efficiency and digital payments between the stakeholders, but more importantly, will offer opportunities to reduce the overall cost of healthcare in the United States" shared Pete Orologas - Vice President and Managing Partner of Predica US.

[Thugmuffin]

$ORHB ORHUB ACQUIRES PUR BIOLOGICS, ENTERING THE GLOBAL MEDICAL DEVICE MARKETPress Release | 04/25/2022

"PURs technologies will bring new solutions for pain elimination and osteoarthritis.


IRVINE, CA / April 25, 2022 - ORHub, Inc. (OTC Pink: ORHB) announced today it has purchased 100% of the equity interest and assets of PUR Biologics, LLC.


ORHub will enter the global medical device market, expected to reach $445.1 billion by 2026. With top categories in the USA including Hip, Knee, & Spine, reaching $75 billion, ORHub will utilize PURs proprietary technologies to regenerate cartilage, mitigate pain, and address the biological causes of degenerative disc disease and osteoarthritis of joints.


We plan to offer improved treatments for age-related joint pain and the degeneration of cartilage in orthopedic indications. Technologies like PURs can enable new ways to address the underlying cause of undesired inflammation and pain signals, while igniting our bodys natural healing capabilities, shared CJ Wiggins - Founder, Executive Chairman, President & CEO for ORHub. We are excited about this acquisition and the opportunity to advance autologous cell and cellular derived therapeutics for osteoarthritis and degenerative disc disease.


PUR Biologics has cultivated innovative technologies, in addition to our full line of bone regeneration products currently on the market. We have identified and secured intellectual property that will finally address major gaps in medical treatment. ORHub is the ideal acquisition partner, with both the necessary science and business structure to take our technologies to the global market, explained Ryan Fernan, former CEO of PUR Biologics.


With this addition to ORHub, plans are being made to update the corporate branding and ticker symbol to encompass its Digital Technology and Regenerative Therapeutic division as it continues its preparations for an audit and up-listing.


--------------
Additional upcoming information:
For more on ORHub, visit: www.ORHub.com
Connect with ORHub on LinkedIn: linkedin.com/company/orhub

Follow @ORHub on Twitter: twitter.com/orhub


About ORHub, Inc.
ORHub, Inc. (OTC: ORHB) is headquartered in Irvine, California. The company is focused on the Internet of Things (IoT), creating Intelligent Automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHubs solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility.


###


Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ORHubs products and services, the results from use of ORHubs products and services, and general business conditions, particularly within the surgical, life science, and medical device industries. Any forward-looking statements contained in this press release are based upon ORHubs historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ORHubs expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Further information on potential risks that could affect actual results will be included in future filings made by ORHub and are available on the Companys website at ORHub.com from time to time.


Contact:

Jason Brown

ORHub, Inc.

612-209-7565

[logytwo]

IRVINE, CA / ACCESSWIRE / April 25, 2022 / ORHub, Inc. (OTC PINK:ORHB) announced today it has purchased 100% of the equity interest and assets of PUR Biologics, LLC.

ORHub will enter the global medical device market, expected to reach $445.1 billion by 2026. With top categories in the USA including Hip, Knee, & Spine, reaching $75 billion, ORHub will utilize PUR's proprietary technologies to regenerate cartilage, mitigate pain, and address the biological causes of degenerative disc disease and osteoarthritis of joints.

"We plan to offer improved treatments for age-related joint pain and the degeneration of cartilage in orthopedic indications. Technologies like PUR's can enable new ways to address the underlying cause of undesired inflammation and pain signals, while igniting our body's natural healing capabilities," shared CJ Wiggins - Founder, Executive Chairman, President & CEO for ORHub. "We are excited about this acquisition and the opportunity to advance autologous cell and cellular derived therapeutics for osteoarthritis and degenerative disc disease."

"PUR Biologics has cultivated innovative technologies, in addition to our full line of bone regeneration products currently on the market. We have identified and secured intellectual property that will finally address major gaps in medical treatment. ORHub is the ideal acquisition partner, with both the necessary science and business structure to take our technologies to the global market," explained Ryan Fernan, former CEO of PUR Biologics.

With this addition to ORHub, plans are being made to update the corporate branding and ticker symbol to encompass its Digital Technology and Regenerative Therapeutic division as it continues its preparations for an audit and up- listing.

[Thugmuffin]

$ORHB ORHUB PREPARES TO FINALIZE ACQUISITION OF PUR BIOLOGICSPress Release | 04/15/2022


"ORHub plans to use PURs patented technologies to treat osteoarthritis & joint cartilage


ORHub, Inc. (OTC Pink: ORHB) announced today it has reached a Definitive Agreement and successfully completed its due diligence of PUR Biologics, LLC.


While FutureORTM digitizes the payment process & implant accountability for PUR product sales, our goal is to replace the dated use of cortisone, lubricants, and other temporary injectables with PURs regenerative and anti-inflammatory technologies, shared CJ Wiggins - Founder, Executive Chairman, President & CEO for ORHub.


Healthcare is evolving and adopting digital business and biologic clinical solutions which have proven value for their organizations and patient outcomes. PURs advanced technologies bring the opportunity to address a largely unmet patient need associated with aging or injured joints. We believe these types of technologies can eliminate pain signals and restore damaged tissue or degenerated cartilage - ultimately improving functional outcomes and the quality of an active life.


--------------
Additional upcoming information:
For more on ORHub, visit: www.ORHub.com
Connect with ORHub on LinkedIn: linkedin.com/company/orhub

Follow @ORHub on Twitter: twitter.com/orhub


About ORHub, Inc.
ORHub, Inc. (OTC: ORHB) is headquartered in Irvine, California. The company is focused on the Internet of Things (IoT), creating Intelligent Automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHubs solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility.


###


Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ORHubs products and services, the results from use of ORHubs products and services, and general business conditions, particularly within the surgical, life science, and medical device industries. Any forward-looking statements contained in this press release are based upon ORHubs historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ORHubs expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Further information on potential risks that could affect actual results will be included in future filings made by ORHub and are available on the Companys website at ORHub.com from time to time.


Contact:

Jason Brown

ORHub, Inc.

612-209-7565

[logytwo]

ORHub Prepares To Finalize Acquisition Of Pur Biologics
Fri, April 15, 2022, 9:10 AM


IRVINE, CA / ACCESSWIRE / April 15, 2022 / ORHub, Inc. (OTC Pink:ORHB) announced today it has reached a Definitive Agreement and successfully completed its due diligence of PUR Biologics, LLC.

"While FutureORTM digitizes the payment process & implant accountability for PUR product sales, our goal is to replace the dated use of cortisone, lubricants, and other temporary injectables with PUR's regenerative and anti-inflammatory technologies," shared CJ Wiggins - Founder, Executive Chairman, President & CEO for ORHub.

"Healthcare is evolving and adopting digital business and biologic clinical solutions which have proven value for their organizations and patient outcomes. PUR's advanced technologies bring the opportunity to address a largely unmet patient need associated with aging or injured joints. We believe these types of technologies can eliminate pain signals and restore damaged tissue or degenerated cartilage - ultimately improving functional outcomes and the quality of an active life."

[Thugmuffin]

$ORHB ORHub, Inc. the Courts Rule To "Dismiss With Prejudice" the Lawsuit Brought by Frederic J. Buonincontri & Axt Analytics, LLCPress Release | 04/05/2022

IRVINE, CA / ACCESSWIRE / April 5, 2022 / ORHub, Inc. (OTC PINK:ORHB) ORHub announced today it has received the court ruling of an "ORDER DISMISSING WITH PREJUDICE" the litigation brought by Frederic Buonincontri and AXT Analytics, LLC in the Superior Court of the State of Arizona in and for the County of Maricopa. Honorable M. Scott McCay issued the Court Order Dismissing the case With Prejudice on March 30, 2022.

"We are very pleased with the Court's decision," CJ Wiggins, Founder, Executive Chairman, President, & CEO for ORHub, "The fact that the case was specifically ‘Dismissed with Prejudice' ensures these parties cannot continue this frivolous activity, wasting our time and resources."

"With the burden of litigation behind us, we can continue, unimpeded, on our path accomplishing our Company's goals of restoring shareholder value, deploying our new FutureORTM software platform, focusing on sales, and acquiring additional technologies and companies synergistic to our business design. Vindicated and energized, we move forward to the next phase of our business."

Additional upcoming information:
For more on ORHub, visit: www.ORHub.com
Connect with ORHub on LinkedIn: linkedin.com/company/orhub
Follow @ORHub on Twitter: twitter.com/orhub

About ORHub, Inc.
ORHub, Inc. (OTC:ORHB) is headquartered in Irvine, California. The company is focused on the Internet of Things (IoT), creating Intelligent Automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHub's solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility.

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ORHub's products and services, the results from use of ORHub's products and services, and general business conditions, particularly within the surgical, life science, and medical device industries. Any forward-looking statements contained in this press release are based upon ORHub's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ORHub's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Further information on potential risks that could affect actual results will be included in future filings made by ORHub and are available on the Company's website at ORHub.com from time to time.

Contact:
Jason Brown
ORHub, Inc.
612-209-7565

[Thugmuffin]

$ORHB ORHub, Inc. THE COURTS RULE TO “DISMISS WITH PREJUDICE” THE LAWSUIT BROUGHT BY FREDERIC J. BUONINCONTRI & AXT ANALYTICS, LLCPress Release | 04/05/2022


ORHub announced today it has received the court ruling of an "ORDER DISMISSING WITH PREJUDICE" the litigation brought by Frederic Buonincontri and AXT Analytics, LLC in the Superior Court of the State of Arizona in and for the County of Maricopa. Honorable M. Scott McCay issued the Court Order Dismissing the case With Prejudice on March 30, 2022.


"We are very pleased with the Courts decision, CJ Wiggins, Founder, Executive Chairman, President, & CEO for ORHub, The fact that the case was specifically Dismissed with Prejudice ensures these parties cannot continue this frivolous activity, wasting our time and resources.


With the burden of litigation behind us, we can continue, unimpeded, on our path accomplishing our Companys goals of restoring shareholder value, deploying our new FutureOR(TM) software platform, focusing on sales, and acquiring additional technologies and companies synergistic to our business design. Vindicated and energized, we move forward to the next phase of our business.


--------------


Additional upcoming information:
For more on ORHub, visit: www.ORHub.com


Connect with ORHub on LinkedIn: linkedin.com/company/orhub

Follow @ORHub on Twitter: twitter.com/orhub


About ORHub, Inc.
ORHub, Inc. (OTC: ORHB) is headquartered in Irvine, California. The company is focused on the Internet of Things (IoT), creating Intelligent Automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHubs solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility.


###


Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ORHubs products and services, the results from use of ORHubs products and services, and general business conditions, particularly within the surgical, life science, and medical device industries. Any forward-looking statements contained in this press release are based upon ORHubs historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ORHubs expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Further information on potential risks that could affect actual results will be included in future filings made by ORHub and are available on the Companys website at ORHub.com from time to time.


Contact: Jason Brown

ORHub, Inc.

612-209-7565

[logytwo]

ORHub, Inc. the Courts Rule To "Dismiss With Prejudice" the Lawsuit Brought by Frederic J. Buonincontri & Axt Analytics, LLC
We are very pleased with the Court's decision," CJ Wiggins, Founder, Executive Chairman, President, & CEO for ORHub, "The fact that the case was specifically ‘Dismissed with Prejudice' ensures these parties cannot continue this frivolous activity, wasting our time and resources."

"With the burden of litigation behind us, we can continue, unimpeded, on our path accomplishing our Company's goals of restoring shareholder value, deploying our new FutureORTM software platform, focusing on sales, and acquiring additional technologies and companies synergistic to our business design. Vindicated and energized, we move forward to the next phase of our business."

[Nazar3]

Hi we’re here.

[AskMuncher]

$ORHB ORHUB ANNOUNCES SEAN MCMENAMIN AS AN INDEPENDENT MEMBER OF THE BOARD
Press Release | 12/06/2021




IRVINE, CA December 6, 2021 - ORHub, Inc. (OTC: ORHB) ORHub today announces Sean McMenamins addition to the Board of Directors. Mr. McMenamin will help to provide board level oversight of the Companys leadership, potential acquisitions, and audits. I am grateful Mr. McMenamin accepted the invitation to join the Board, as he compliments the team with additional financial expertise. He is highly talented, capable, and a great fit, expressed CJ Wiggins, MBA - ORHub Founder, Executive Chairman, President, & CEO.



The opportunity ORHub has to improve financial transactions and business efficiency for hospitals and medical device manufacturers is impressive, stated Mr. McMenamin. The industry is in need of a solution and the financial impact will be a win for everyone.



Mr. McMenamin understands what we are doing, brings great vision, and offers an independent insight which is beneficial to us all. stated Melissa Moore, Corporate Secretary & VP of Operations.





--------------



Additional upcoming information:
For more on ORHub, visit: www.ORHub.com
Connect with ORHub on LinkedIn: linkedin.com/company/orhub Follow @ORHub on Twitter: twitter.com/orhub



About ORHub, Inc.
ORHub, Inc. (OTC: ORHB) is headquartered in Irvine, California. The company is focused on the Internet of Things (IoT), creating Intelligent Automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHubs solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility.



###



Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ORHubs products and services, the results from use of ORHubs products and services, and general business conditions, particularly within the surgical, life science, and medical device industries. Any forward-looking statements contained in this press release are based upon ORHubs historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ORHubs expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Further information on potential risks that could affect actual results will be included in future filings made by ORHub and are available on the Companys website at ORHub.com from time to time.



Contact:

Jason Brown

ORHub, Inc.

612-209-7565

[AskMuncher]

$ORHB ORHUB ENTERS THE HOLIDAYS, GENERATING REVENUE THROUGH CONTINUED CUSTOMER AGREEMENT
Press Release | 12/01/2021




Six-figure revenue event & customer requests for FutureORTM, demonstrate ORHubs effort to Transform the Business of SurgeryTM is on target.





IRVINE, CA - December 1, 2021 - ORHub, Inc. (OTC: ORHB) The Companys strategic design is to deliver technological solutions, which improve business processes, increase customer earnings, support patients functional outcomes, and enable a mobile ecosystem for patient connectivity.



We are Innovators and Sales Professionals of healthcare technologies, said CJ Wiggins, MBA - ORHub Founder, Executive Chairman, President, & CEO. I believe nothing happens without productivity and positive impact. Effective productivity is the successful action of closing sales and improving healthcare. Positive impact is a mind-set, and core to our culture.



ORHub has set its sights on launching the FutureORTM & V-PayTM applications in Q2 2022. The Company continues its efforts of closing sales and managing cash-flow, while developing and acquiring future technologies, with the collective purpose of delivering business, social, and patient benefits.



--------------



Additional upcoming information:
For more on ORHub, visit: www.ORHub.com
Connect with ORHub on LinkedIn: linkedin.com/company/orhub Follow @ORHub on Twitter: twitter.com/orhub



About ORHub, Inc.
ORHub, Inc. (OTC: ORHB) is headquartered in Irvine, California. The company is focused on the Internet of Things (IoT), creating Intelligent Automation and connected mobility solutions to help revolutionize healthcare for a more sustainable and connected future. ORHubs solutions create intelligent data, activate new and improved methods of managing multi-vendor transaction details, and digitize payments, all of which improve the necessary and undervalued business relationship between hospital customers and supporting medical device and biotech vendors. These solutions are believed to form a valuable foundation for potential new uses of AI, future of quantum computing, and a mobile ecosystem for personalized implant and other patient centered information and accessibility.



###



Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ORHubs products and services, the results from use of ORHubs products and services, and general business conditions, particularly within the surgical, life science, and medical device industries. Any forward-looking statements contained in this press release are based upon ORHubs historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ORHubs expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Further information on potential risks that could affect actual results will be included in future filings made by ORHub and are available on the Companys website at ORHub.com from time to time.



Contact: Jason Brown

ORHub, Inc.

612-209-7565

[logytwo]

Mon, November 29, 2021, 6:00 AM
In this article:

ORHB
+2.70%

"ORHub aims for Q2, 2022 to bring total implant accountability to the medical device & surgical industry"

IRVINE, CA / ACCESSWIRE / November 29, 2021 / ORHub, Inc. (OTC PINK:ORHB) has invested in developing a flexible, scalable, and secure "Surgical Resource Management" (SRM) operating system focused on Intelligent Automation. This will allow for the delivery of implant accountability, business efficiency, communication portals, and digital transactions between hospitals and their medical device & biologic vendors.

"Today's cost-of-care is unsustainable. Fortunately, current technologies have allowed us the opportunity to remedy this situation," stated CJ Wiggins, MBA - ORHub Founder, Executive Chairman, President, & CEO. "How we currently capture, share, and record surgical implant information causes business and administrative inefficiency, risk to patient's care, and an increased cost to patients, hospitals, and vendors. FutureORTM is the game changer that the industry needs."

"I believe within 36 months, the entire process by which hospitals and device manufacturers conduct business and collect, transact, & account for surgical implant information will be completely transformed, for the better," shared Mr. Wiggins.

[logytwo]

forward strategy."

IRVINE, CA / ACCESSWIRE / November 23, 2021 / ORHub, Inc. (OTC PINK:ORHB) provides a 2021 update and announces the Company is prepared to accelerate its agenda in 2022. "We continue to perform and over the last year, have made huge commitments, and taken all necessary steps to successfully protect our shareholders, the company, and our team," shared CJ Wiggins, MBA - ORHub Founder, Executive Chairman, President, & CEO. "There are more opportunities today than ever in our industry, and I am confident in the future of ORHub to change business for good."

It has been a busy 2021 for ORHub. While continuing to generate revenue with current technologies, ORHub reduced its debt by over $7.5M. Retaining an Irvine-based, Microsoft Gold Partner, the company has developed a new platform delivering a first-of-kind digital payment process and life cycle management of surgically implanted biomedical devices.

In addition to new product developments, ORHub retained former SEC & accounting firms and met new SEC reporting requirements. While divesting ORHub's old technology, SugicalSpotlight, the company identified and engaged in preliminary discussions for an acquisition target with potential short- and long-term value.

ORHub entered into a binding "Settlement Agreement" with Note Holders, in turn receiving the Note Holders' complete surrender of all Note Agreements. ORHub delivered on all settlement requirements and received Note Holders' full release of any & all liabilities. With these actions taken, ORHub filed a "Motion to Enforce Settlement" for the "withdrawal, with prejudice" of long-standing litigation.

"I cannot express the level of gratitude I have for the commitment and performance delivered by our team over the past 18 months. They have energetically pursued our business goals and persistently innovated our new product developments, which has enabled the company to return to financial health," commented Mr. Wiggins.

On the trajectory and focus of the company, Mr. Wiggins states, "I am committed to the stakeholders and our opportunity to impact society for the better. With our significant reduction in debt and support from our strategic partners, I am confident we will meet our new year's goals to launch product, continue acquisition discussions, and preparing for our audit and plans for up-listing."

-

[$on_myMind]

hmm

[$on_myMind]

verified profile and low float tick tock

[Derpo]

They haven't had an engineering team since December, so I'd say they are as good as dead.

[Cuervman]

Anyone hear anything at all recently?

[TheFINEST]

Are we dead again here? Radio silence from the company.

[logytwo]

After yesterday, I'm guessing someone knows something.........

[TheFINEST]

Link to news?

[GrabThatCash]

News out ! Wow, this is better late than never,either way its exactly what we needes to trigger sales.

[TheFINEST]

Now we’re finally cooking here.

[logytwo]

Physician Leaders at a Southern California Ambulatory Surgery Center choose ORHub to activate data driven decisions to improve patient care and increase profits in 2020

LAGUNA BEACH, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – ORHub, Inc. (OTC: ORHB; the “Company”), a Microsoft Silver Partner and cloud-based digital health company focused on improving the efficiency of the operating room and optimizing the cost-of-care by delivering actionable clinical and business intelligence through a centralized platform to care providers, administration and leaders, today announces a new customer partnership with a premier Ambulatory Surgery Center (“ASC”).

[Derpo]

Orhub had a full time engineering team and now they literally have none. Not even their "vp" remains at this point.

This is going to be as fruitful as their block-chain partnership.

[logytwo]

ORHub, Inc. and eHealthAnalytics Announce a Strategic
Relationship to Improve Cost Transparency and Device Success

CEOs Dr. Robert Lazzara and Gail Port plan to Unveil their
Pre-Operative Product at StartUp Health in January 2020

TEMPE, Ariz., January 2, 2020 -- ORHub, Inc. (OTC: ORHB) ORHUB Inc., a Microsoft Silver Partner and SaaS based surgical analytics company that educates surgeons on cost effective behavior, and eHealthAnalytics, a company built around the use of predictive analytics in healthcare with a focus on medical device adverse events and recalls, are pleased to announce their agreement to form a strategic relationship built around the development of a unique product in healthcare. The companies will jointly unveil their work at the StartUp Health conference in San Francisco on January 13-14, 2020.

The new product, once completed, would allow healthcare organizations and surgeons to assess predicted cost of procedures, and the probability and financial impact of a recall on selected devices, pre-operatively. “Our work with ORHub will broaden the financial knowledge base for perioperative leadership when it comes to use of all medical devices,” said Gail Port CEO of eHealthAnalytics.

Using tools from ORHub’s Surgical Spotlight® with the predictive models from eHealthAnalytics’ MedDev PredictTM, the platform will be the first of its kind to take into consideration the co-morbid conditions of pre-operative patients. Not only will this allow for cost transparency before a surgical event, but also offer surgical teams information about the chosen devices for each patient. “From a clinical point of view our unveiling of this new development with eHealthAnalytics, will be a major step forward for all surgical specialties and patient care,” said Dr. Robert “Bobby” Lazzara, CEO of ORHub.

[Cuervman]

My assumption would be that if a hospital was going to implement a new process like this they’ll do their due diligence on the company itself to make sure it’s not going to go insolvent and waste their time training their staff. Simple google search will pull up enough to give them second thoughts right now.

[Derpo]

How exactly is that going to help the company sell? Given the supposed value prop, this stuff should be selling itself and yet they can only get it into hospitals already connected to their leadership.

[TheFINEST]

Hope you’re right. No point in selling now

[logytwo]

I think we will come out the other end, the court has been siding mostly with the company. The note and share holders are mounting a legal challenge to those trying to take the company down, looking to punish them as well.